Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 10, 2018

SELL
$6.7 - $12.95 $3.35 Million - $6.48 Million
-500,000 Closed
0 $0
Q4 2017

Feb 12, 2018

BUY
$5.07 - $7.92 $2.54 Million - $3.96 Million
500,000
500,000 $3.21 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Sphera Funds Management Ltd. Portfolio

Follow Sphera Funds Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.